Abstract

Background: Insulin is essential for managing diabetes mellitus (DM), and while hypersensitivity reactions to insulin are uncommon, they have been observed since the introduction of animal-derived insulin. The incidence of such reactions has decreased with the advent of human insulin produced through recombinant DNA technology. This case study explores a rare hypersensitivity reaction to insulin glargine in a patient with Type-2 DM.
Case Presentation: A 64-year-old male with Type-2 DM and impaired kidney function experienced an immediate hypersensitivity reaction (Type-1) at the subcutaneous injection sites of insulin glargine. Despite receiving the prescribed dose under medical supervision, the patient exhibited widespread erythema, rashes, and itching at the injection sites.
Conclusion: This case highlights the complexities of managing hypersensitivity reactions to specific insulin formulations, such as insulin glargine. Close monitoring and individualized treatment strategies are crucial to balance effective glycemic control with minimizing adverse reactions in diabetic patients.

Key words: Keywords: Insulin, Type 2 Diabetes Mellitus, Insulin Glargine, Hypersensitivity Reaction, Erythema, Glycemic Control, Case Report.